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Abstract
Gynecological tumors are major therapeutic areas of platinum-based anticancer drugs. Here,
we report the characterization and in vitro biological assays of cisplatin-containing Egg
L-a-phosphatidylcholine liposomes with different amounts of cholesterol. Dynamic light
scattering estimated sizes of all obtained liposomes in the 100 nm range that are suitable for
in vivo use. On the basis of these data and of the drug loading values, the best formulation has
been selected. Stability and drug release properties of platinum-containing liposomes have
been verified in serum. The growth inhibitory effects of both liposomal and free drug in a panel
of ovarian and breast human cancer cell lines, characterized by a different drug sensitivity, give
comparable or better results with respect to free cisplatin drug.
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Introduction
Since the clinical introduction, more than 40 years ago,
platinum containing drugs are widely employed as chemother-
apeutic agents for the treatment of a variety of human cancers
(Kelland, 2007). Ovarian and breast cancer are major
therapeutic areas of platinum-based anticancer drugs.
Cisplatin (CDDP) is very effective in the treatment of ovarian
cancer, and, recently, the interest in platinum-based chemo-
therapy for breast cancer has also been renewed, based on the
hypothesis of greater susceptibility of triple-negative and
BRCA1/2-mutant tumors (Muggia & Safra, 2014).
Although very active, the dose limiting side effects of
CDDP, including nephrotoxicity, peripheral neuropathy and
ototoxicity, hamper dose increase and inhibit its extensive
clinical use (Burger et al., 1999; Howe-Grant & Lippard,
1980; Reedijk, 1999). Moreover, in many cases, patients
respond to first-line treatment, but the majority ultimately
develops a platinum-resistant disease. Several mechanisms
underlying the multifactorial CDDP-resistance phenotype
have been described (Galluzzi et al., 2012). Importantly, a
decreased intracellular drug accumulation is a common
feature of CDDP-resistant tumor cell lines; and a relationship
between tumor tissue platinum concentration and therapeutic
response in clinical settings has also been recently highlighted
(Kim et al., 2012). These findings demonstrate that mechan-
isms underlying platinum drug transport and accumulation in
tumor cells are important determinants for tumor selectivity
and treatment effects.
Many ways have been searched to overcome these
drawbacks. One opportunity is to develop new platinum
analogs or platinum prodrugs, which are able to decrease
the cellular proliferation and at the same time reduce the
side effects (Lovejoy & Lippard, 2009). However, some
drawbacks and resistance persist and neither of analogs
showed significantly better results than CDDP (Wheate et al.,
2010).
Another way is based on nanotechnologies that are recently
developed. Nanocarrier-based delivery of platinum drugs to
the tumor sites is a promising strategy for improving tumor
selectivity, and encouraging preclinical and clinical results
have been reported (Oberoi et al., 2013).
To the best of our knowledge, five platinum containing
supramolecular aggregates are in clinical evaluation. The first
liposomal formulation studied in the clinic for the delivery
of a CDDP analog (cis-bis-neodecanoato-trans-R, R-1,2-
diaminocyclohexane platinum II, NDDP) was L-NDDP
(AroplatinTM, Antigenics Inc, Lexington, MA) (Vadiei
et al., 1992). Liposomes were obtained mixing 1,2-
dimyristoylphosphatidylcholine (DMPC) and 1,2-dimyristoyl-
phosphatidylglycerol (DMPG) lipids. Preclinical data showed
that L-NDDP had a completely different biodistribution
from that of NDDP, with an accumulation of platinum in
major organs, such as the liver, spleen and lymph nodes.
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Another long-circulating aggregate is SPI 077 (Alza
Corporation, Mountain View, CA). This drug is based
on liposomes formulated by Hydrogenated Soy
Phosphatidylcholine (HSPC)/cholesterol/1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[amino(polyethylene
glycol)-2000] (DSPE-PEG2000) and loaded with CDDP by
using the loading passive method (Newman et al., 1999).
Although this supramolecular aggregate shows enhanced
pharmacokinetic properties with respect to CDDP, SPI 077
did not produce significant clinical response rates in several
Phase II studies. The major limit of lack of therapeutic
efficacy is due to slow and low release of platinum drug from
aggregates, as shown in preclinical studies (Harrington et al.,
2001).
A more recent CDDP-containing long-circulating liposo-
mal formulation is LipoplatinTM (Regulon Inc, Mountain
View, CA) (Stathopoulos & Boulikas, 2012). This formula-
tion differs from the SPI 077 in several basic principles
including loading method, based on reverse micelles, anionic
lipids like 1,2 dipalmitoylphosphatidylglycerol (DPPG) added
in the phospholipids mixture and a higher drug content 1:10
versus 1:70 drug/lipid reported for SPI 077.
In several Phase I, II and III studies, Lipoplatin was shown
to reduce renal toxicity, peripheral neuropathy, ototoxicity,
and myelotoxicity substantially with improved or comparable
efficacy to CDDP (Boulikas, 2009). The same company
developed LipoxalTM (Stathopoulos et al., 2006), an oxali-
platin delivering liposomal formulation. In a Phase I study
using Lipoxal, reduction respect to free oxaliplatin of
myelotoxicity, nausea and peripheral neuropathy was
observed. Further clinical tests will be needed to demonstrate
the improvement of antitumor activity of Lipoxal over free
oxaliplatin.
LiPlaCis (LiPlasome Pharma ApS – Denmark) (de Jonge
et al., 2010), liposomes obtained mixing 1,2-disteroylpho-
sphatidylcholine (DSPC)/1,2-disteroylphosphatidylglycerol
(DSPG)/DSPE-PEG2000 were designed to be degraded by
secretory phospholipase A2 (PLA2), a relatively tumor
selective enzyme, releasing the encapsulated CDDP. Renal
toxicity and acute infusion in the Phase I stage of LiPlaCis led
to early cessation of this particular formulation: LiPlaCis
requires reformulation to enable further development. In
parallel, the same company is testing Liploxa, another
oxaliplatin-loaded liposomal formulation. Many different
other supramolecular aggregates have been developed in the
last years, in preclinical phase, using a novel approach based
on hybrid nucleoside-lipids (Khiati et al., 2011). The nucleo-
side polar heads guide the self-assembly of the aggregates
into highly loaded and stable CDDP nanoparticles.
Very innovate systems based on aggregation of platinum
containing monomers were recently reported for delivery of
platinum-based drugs. These systems integrate drugs into the
lipid composition, leading to an extremely high drug-to-lipid
ratio. In Aryal et al. (2012), two hydrophobic acyl chains were
bound to the Pt(II) center to provide amphiphilic properties to
the platinum monomer; in Accardo et al. (2013), the
same results were achieved coordinating the metal to
amino-EtGly-PEG27-(C18)2 amphiphilic. Both molecules are
able to self-assemble in supramolecular aggregates, and in
the second case the platinum-based monomer is also able to
co-aggregate with a second amphiphilic monomer containing
the octreotide bioactive peptide able to recognize somatosta-
tin receptor type II (SSTR2) overexpressed in many cancer
tissues. However, these studies provide only preliminary
results without indication on their in vivo effects.
The literature suggests that design and preparation of
liposomal nanovehicles require to achieve a balance between
their stability in vivo, encapsulation efficiency, drug release,
biodistribution and cytotoxic activity. The current liposomal
formulations have primarily taken advantage of reduced
systemic toxicity rather than increased efficacy.
In this study, we encapsulate CDDP in Egg L-a-phosphat-
idylcholine (PC) liposomes containing different amounts of
cholesterol. The Egg PC is a mixture of molecular species of
PC differing in fatty acyl chains, and it includes a consider-
able amount of unsaturated fatty acids, such as arachidonic
(C20:4) and decasohexanoic (C22:6) acids. Its stability
and properties are well known in the literature (Grit et al.,
1993).
Phosphatidylcholine was selected as a phospholipid, since
it represents a good compromise between saturated or
unsaturated phospholipids. The unsaturated bond increases
fluidity and permeability with respect to HSPC used in other
preparations and currently tested in clinical phase. The lower
stability of the aggregates may be increased adding cholesterol
to the phospholipids mixture. The presence of cholesterol
exerts a deep influence on the properties of lipid bilayers of the
liposomes. It has been well known that cholesterol addition to
unsaturated lipids decreases both membrane permeability to
water and flexibility of the surrounding lipid chains, favoring
retention of encapsulated content.
The SPI 077 formulation, containing 44% of cholesterol in
weight, shows a low release of platinum drug from aggregates
(Harrington et al., 2001). Therefore, we prepared two
different formulations using lower amounts of cholesterol
(PC/Chol weight ratio 80:20 and 70:30) in order to increase
platinum release. The growth inhibitory effects of both
liposomal drug and free drug in a panel of ovarian and




Phosphatidylcholine and cholesterol (Chol) were purchased
from Avanti Polar Lipids (Alabaster, AL). SnakeSkinTM
Dialysis Tubing was purchased by Thermo Scientific Pierce
Protein Research Products (Waltham, MA). CDDP and all
other chemicals were commercially provided by Sigma-
Aldrich (Bucks, Switzerland) or LabScan (Stillorgan, Dublin,
Ireland) and were used as received unless further purification.
All the solutions were prepared by weight with bidistilled
water.
Liposomes were extruded using a thermobarrel extruder
system (Northern Lipids Inc, Vancouver, BC, Canada).
Inductively coupled plasma atomic emission (ICP-AES)
measurements were carried out using an inductively coupled
plasma atomic emission spectrometer (ICP SPECTRO Arcos
with EndOnPlasma torch; Spectro Analytical, Kleve,
Germany) equipped with a capillary cross-flow nebulizer.


































Liposomes preparation and CDDP loading
Empty aggregates composed of PC and PC/Chol at different
molar ratios were prepared by the thin film method. The two
amphiphiles dissolved in a small amount of MeOH/CHCl3
(50/50) were mixed in appropriate amounts to obtain a final
lipid concentration of 2 mM. Subsequently, a thin film was
obtained by evaporating the organic solvents by slowly
rotating the vial containing the solution under a gentle
stream of nitrogen. Lipid films were then hydrated in 100 mM
phosphate-buffered saline (PBS) containing 0.9% w/w of
NaCl, sonicated for 30 min and extruded 10 times at room
temperature through a polycarbonate membrane with 100 nm
pore size, using a thermobarrel extruder system under N2.
CDDP was encapsulated into liposomes using the passive
equilibration loading method. Preformed liposomes were
warmed at 60 C for 5 min before adding to pre-warmed
CDDP powder. The external CDDP concentration used was
1 mg/1 mL. The mixture was incubated at the above indicated
temperature for 1.5 h in a water bath under stirring, then
cooled to room temperature. Unencapsulated CDDP was
removed first by centrifugation at 13 400 rpm at room
temperature for 15 min and then loading the supernatant on
pre-equilibrated Sephadex G50 column. Liposomal fractions
were collected and analyzed by ICP-MS to determine
platinum content.
Dynamic light scattering characterization
Dynamic light scattering (DLS) measurements were carried
out using a Zetasizer Nano ZS (Malvern Instruments,
Westborough, MA) that employs a 173 backscatter detector.
Other instrumental settings are measurement position (mm):
4.65; attenuator: 8; temperature 25 C; cell: disposable sizing
cuvette. Before starting with DLS measurements, previously
prepared samples were diluted at final concentration of
2.0 104 M and centrifuged at room temperature at
13 000 rpm for 5 min. For each formulation, RH and P.I.
were calculated as the mean of three measurements on three
different batches.
Serum stability
Cisplatin-loaded liposomes were prepared in 100 mM phos-
phate buffer at pH 7.4 containing 0.9% NaCl at 4 mM lipid
concentration and then diluted at 2 mM with fetal
bovine serum (FBS; Biowest, Nuaille´, France). The colloidal
suspension was stirred at 37 C for 72 h. Samples withdrawn
at different time points (30 min, 1 h, 2 h, 4 h, 8 h, 12 h,
24 h, 28 h, 36 h, 48 h and 72 h) were diluted with PBS (1:50
v/v) and analyzed by dynamic light scattering as described
earlier.
CDDP release in serum
A total of 500 mL of FBS were added to 500 mL of a 4 mM
CDDP-loaded liposomes prepared according the protocol
described above. The final FBS/liposome solution (50/50 v/v)
was transferred into a dialysis bag (MW cut-off¼ 3500 Da).
Then the sample was placed into 15 mL of FBS/PBS (50/50)
mixture and incubated under stirring for 24 h at 37 C. At
appropriate intervals, 2 mL aliquots of the dialyzed serum
solution were withdrawn and immediately replaced with an
equivalent amount of fresh serum. The extent of CDDP
release was evaluated by ICP-AES analysis as percentage of
the ratio between the amount of released metal and of the total
metal previously loaded into the liposomes.
A CDDP standard solution (1000 ppm) was used to prepare
nine solutions by sequential dilution in 5% (v/v) aqua regia
(HCl/HNO3 3:1 v/v), to yield the calibration curves in the
range 2–150 ppb. Each sample was mineralized with aqua
regia, using nitric acid and hydrochloric acid in bidistilled
water, to a final aqua regia content of 5% v/v. Analytical
determinations were performed using a plasma power of
1.4 kW, a radiofrequency generator of 27.12 MHz and an
argon gas flow with nebulizer, auxiliary and coolant set at 0.8,
0.8 and 13 L min1, respectively.
Tumor cell lines and in vitro cell growth inhibition
assay
Tumor cell lines representative of breast (MCF7, MDA-
MB-231) and ovarian (SKOV-3) cancers were obtained from
the National Cancer Institute, Biological Testing Branch
(Frederick, MD), and maintained in the logarithmic phase at
37 C in a 5% CO2 humidified air in RPMI 1640 medium
supplemented with 10% fetal calf serum, 2 mM glutamine,
penicillin and streptomycin (100 U/mL and 0.1 mg/mL,
respectively). The human ovarian cancer cell line A2780
from an untreated patient, and the A2780cp8 CDDP-resistant
subline were originally obtained from Dr R Ozols (Behrens
et al., 1987) and cultured in RPMI 1640 medium supple-
mented with 10% fetal calf serum, 2 mM glutamine, 10 mg/mL
gentamycin and 10 mg/mL insulin.
The growth inhibitory effect of compounds under inves-
tigation was evaluated by using the sulforhodamine B assay
(Skehan et al., 1990). Briefly, cells were seeded into 96-well
microtiter plates in 100 mL at a plating density of 5000 cells/
well. After seeding, microtiter plates were incubated at 37 C,
5% CO2, 95% air and 100% relative humidity for 24 h prior to
addition of the compounds. After 24 h, several samples of
each cell line were fixed in situ by a gentle addition of cold
50% (w/v) trichloroacetic acid (TCA, 10% final concentra-
tion), to represent a measurement of the cell population at the
time of compound addition. Cells were treated for 72 h with
different concentrations of free CDDP, liposomal CDDP, or
empty liposome dissolved at in 0.1 M PBS, pH 7.4, 0.9%
NaCl and stepwise diluted to the desired final concentration
with complete cell culture medium. At the end of treatment
time, the cells were fixed in situ with cold TCA and incubated
for 1 h at 4 C. The supernatant was discarded, and the plates
were washed four times with tap water and air-dried.
Sulforhodamine B (SRB) solution (100 mL) at 0.4% (w/v) in
1% acetic acid was added to each well, and plates were
incubated for 30 min at room temperature. After staining,
unbound dye was removed by washing five times with 1%
acetic acid and the plates were air-dried. Bound stain was then
solubilized with 10 mM Trizma base and the absorbance was
read on an automatic plate reader at 515 nm. The compound
concentration able to inhibit cell growth by 50% (IC50 ± SD)
was then calculated from semilogarithmic dose-response
plots.



































Preparation and characterization of CDDP-containing
liposomes
Three different lipid formulations based on EggPC were
prepared, with 0, 20 and 30% (mol/mol) of Chol. All
liposomes were prepared starting from a lipid film, obtained
in MeOH/CHCl3 (50/50) mixture, hydrated with 0.9% w/w of
NaCl containing PBS buffer, by extensive bath sonication.
The colloid solutions were extruded at room temperature
through a polycarbonate membrane with 100 nm pore size in
order to reduce liposome size and obtain unilamellar vesicles.
Cisplatin was loaded into liposomes using the passive
equilibration loading method (Woo et al., 2008). The
unencapsulated CDDP was removed first by centrifugation
and then eluting the supernatant on pre-equilibrated Sephadex
G50 column (GE Healthcare Europe, Freiburg, Germany).
The drug loading contents (DL), measured with respect to the
PC phospholipid content, and the encapsulation efficiencies
are reported in Table 1. The encapsulation CDDP amount was
quantified by means of ICP-AES on liposomal fraction.
A progressive increase of encapsulated CDDP was
observed starting from 0 to 30% of cholesterol. As it
concerns, CDDP encapsulation and release from liposomes,
several factors appear to be critical, and in general factors
improving loading could reduce retention and vice-versa
(Newman et al., 1999; Stathopoulos & Boulikas, 2012). Most
of studied CDDP-containing liposomes are based on formu-
lations having high cholesterol percentages in order to
stabilize the liposome membrane. However, it is known that
these formulations present a difficult CDDP release in vivo. In
our study, we used an unsatured phospholipid to increase
membrane fluidity coupled with increasing amounts of
cholesterol. A formulation with 20% of cholesterol seems a
good compromise to allow a sufficient CDDP loading, leaving
a fluid membrane to permit an efficient drug release in vivo.
The CDDP-loaded liposomes were characterized by DLS
technique. The data are reported in Table 1. Measurements
were performed at y¼ 173 at a concentration of 5 104
molkg1 in 2.0 104 M PBS buffer solution. All aggregates
show a monomodal distribution indicating the presence of a
single population of aggregates. At infinite dilution, RH values
can be reasonably evaluated using the translational diffusion
coefficients in the Stokes–Einstein equation, considering the
high dilution (Accardo et al., 2013). The values are comparable
to PC liposomes previously reported when the 100 nm filters
are used for the extrusion process (Matsuzaki et al., 2000).
Dimensions of all obtained liposomes are suitable for in vivo
use. Results evaluation pushed to follow the in vitro experi-
mentation for PC/Chol 80/20 formulation that has been
selected for the good ratio in drug loading. Moreover,
cholesterol ratio guarantees a right compromise able to
assure at the same time indispensable rigidity and flexibility.
Both properties are crucial parameters in the development of
supramolecular aggregates acting as drug shuttle.
CDDP release and serum stability
Serum stability of CDDP-loaded liposomes, incubated
with FBS/PBS (50/50) mixture, was assessed until 72 h.
After incubation, size of the liposomal suspension was
monitored by DLS measurements upon the time. The
liposomal diameter did not show significant variations
during the first 24 h of observation. After this period, a
progressive increase in the size of the aggregates was
observed, thus indicating an aggregation of the liposomes
with the serum proteins (data not shown). Since the premature
release of the CDDP from the carrier is an undesired event,
due to the well-known severe toxic effects of free platinum
drugs into the blood stream, the release kinetic of the CDDP
from the liposomes in serum was evaluated. According to the
serum stability results, CDDP release from the inner
compartment of the liposomes was studied only until 24 h.
A dialysis bag containing the liposomal suspension was
dipped in a reactor containing 50% of fetal bovine serum in
phosphate buffer, and placed at 37 C under vigorous
agitation for 24 h, and the amount of CDDP released was
estimated by ICP-AES analysis. As shown in Figure 1,
CDDP-loaded liposomes exhibit a low drug release rate: only
2% of the drug was slightly released in the first 10 h,
suggesting that platinum containing liposomes present a very
slow drug release.
Cellular studies
The growth inhibitory effect of both free and liposomal
CDDP was evaluated in a panel of human tumor cell lines
characterized by different CDDP sensitivity and containing
examples of breast (MCF7, MDA-MB-231) and ovarian
(SKOV-3, A2780) cancers. The panel contains ovarian cancer















Figure 1. Release rate of CDDP from liposomes, performed in FBS/PBS
(50/50) mixture. The amount of drug released (%) was estimated by ICP.
Table 1. Drug loading content and structural parameters (hydrodynamic






efficiency (%) RH (nm) ±S.D. PDI
PC 100% 0.0058 0.68 59 ± 40 0.287
PC/Chol 80/20 0.0076 0.71 55 ± 30 0.217
PC/Chol 70/30 0.013 0.81 64 ± 27 0.221


































cells characterized by intrinsic (SKOV-3) or acquired
(A2780cp8) resistance to CDDP. Results are presented in
Figure 2 and Table 2.
After 72 h treatment, only a slight decrease of cell growth
after incubating the cells with liposome
concentrations4200 mM was evident for MDA, MCF7 and
SKOV3 cell lines (Figure 2). In contrast, a similar inhibitory
effect of empty liposome, was detected for both A2780 and
A2780cp8 cell lines, the IC50 being 85.8 and 94.9 mM,
respectively.
A comparison of growth inhibitory activity of free CDDP,
liposomal CDDP and empty liposomes is shown in Table 2.
Across the cell lines, liposomal CDDP was more active than
the free drug (mean IC50¼ 2.0 and 5.6, respectively), and the
inhibitory potency was similar only for A2780 cells.
Moreover, liposomal CDDP shows a narrower range of
activity than CDDP, the most resistant/most sensitive cell line
IC50 ratios being 2.4 and 5.9, respectively. As expected, the
A2780cp8 cell line was about 5-fold more resistant to CDDP
compared to the A2780 cell line. In contrast, liposomal CDDP
maintained its activity towards A2780cp8 cells, the resistance
factor (RF, IC50 A2780cp8/IC50 A2780) being 1.1. However,
a contribution of the liposome itself to the growth inhibition
of the A2780/A2780cp8 pair cannot be excluded, as also
suggested by the inhibitory effect data of the empty liposome
as shown in Figure 2.
Liposomal CDDP was able to overcome CDDP resistance
of ovarian A2780cp8 cells, which had been previously
characterized for having a greater glutathione content
(Behrens et al., 1987) and a reduced drug accumulation
(Coluccia et al., 1999) with respect to the parental cell line.
This property, along with the major activity of liposomal
CDDP towards tumor cells intrinsically resistant to CDDP
(e.g. MCF7 and MDA-MB-231 cells) suggests a distinct
liposome-mediated mechanism of action, perhaps not limited
only to a drug accumulation improvement.
Conclusion
The current scenario about CDDP-loaded liposomes shows
bright and dark features. Most of the classic preparations are
based on saturated lipophilic tails inducing complications in
platinum complex release and its consequential low cytotox-
icity for tumor cells. Present study is a preliminary investi-
gation of new CDDP-loaded liposomes based on Egg PC to
address versus gynecological cancer cells. Structural data,
loading studies and stability measurements allow to ensure
stability of these systems. Liposomes fit within a critical size
range (100–110 nm), the drug loading are comparable to SPI
077 formulations and the drug amount released within 10 h
are suitable to their use in vitro and in vivo. The growth
inhibitory effect of the 80/20 liposome formulation tested in a
panel of cell lines of gynecological tumors shows promising
results at least in the case of A2780cp8 ovarian cells.
Further studies will be carried out in order to introduce
PEG chains in the hydrophilic shell of the liposome formu-
lation, inducing blood circulation increase. Another improve-
ment will be the functionalization with a bioactive peptide
able to recognize receptors overexpressed in gynecological
cancer cells.
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